'''Comirnaty''' брэндээр зарагдажа байдаг,<ref name="Comirnaty EPAR">{{cite web|title=Comirnaty EPAR|url=https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty|access-date=23 December 2020|website=[[European Medicines Agency]] (EMA)|archive-date=17 March 2021|archive-url=https://web.archive.org/web/20210317131756/https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty|url-status=live}}</ref> '''Pfizer–BioNTech COVID-19 вакцин''' ([[Уласхоорондын патентовалхагүй нэрлэлгэ|INN]]: '''tozinameran''') — болбол [[Германи|Германиин]] [[BioNTech]] хампааниин бүтээһэн [[РНХ-вакцина|мРНХ-да]] һуурилһан [[COVID-19-дэ эсэргүү вакцина]] юм. Энэнь [[COVID-19|COVID-19-ые]] үүсхэдэг [[SARS-CoV-2]] вирусай халдабариһаа хамгаалха зорилгоор<ref name="Comirnaty EPAR" /> зарим уласта 12 ба тэрэнһээ дээшэ наһанай, бусад уласта 16 ба тэрэнһээ дээшэ наһанай хүнүүдтэ хэрэглэхые зүбшөөрһэн.<ref>{{cite press release|title=First COVID-19 vaccine approved for children aged 12 to 15 in EU|website=[[European Medicines Agency]] (EMA)|date=28 May 2021|url=https://www.ema.europa.eu/en/news/first-covid-19-vaccine-approved-children-aged-12-15-eu|access-date=29 May 2021|archive-date=28 May 2021|archive-url=https://web.archive.org/web/20210528212329/https://www.ema.europa.eu/en/news/first-covid-19-vaccine-approved-children-aged-12-15-eu|url-status=live}}</ref><ref>{{cite web|title=Information for UK recipients on Pfizer/BioNTech COVID-19 vaccine|publisher=[[Medicines and Healthcare products Regulatory Agency]] (MHRA)|date=8 December 2020|url=https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/information-for-uk-recipients-on-pfizerbiontech-covid-19-vaccine|access-date=29 May 2021|archive-date=30 May 2021|archive-url=https://web.archive.org/web/20210530190316/https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/information-for-uk-recipients-on-pfizerbiontech-covid-19-vaccine|url-status=live}}</ref> [[BioNTech]] нь вакцина бэлэдхэлгэдэ Америкын [[Pfizer]] хампаанитай [[клиникын туршалта]], логистикэ, үйлэдбэрилгын шэглэлээр хамтаран ажаллаһан.<ref>{{cite news|date=11 November 2020|title=What you need to know about BioNTech – the European company behind Pfizer's Covid-19 vaccine|publisher=CNBC|url=https://www.cnbc.com/2020/11/11/biontech-the-european-company-behind-pfizers-covid-19-vaccine.html|access-date=14 January 2021|vauthors=Browne R|archive-date=4 March 2021|archive-url=https://web.archive.org/web/20210304192058/https://www.cnbc.com/2020/11/11/biontech-the-european-company-behind-pfizers-covid-19-vaccine.html|url-status=live}}</ref> Хитадта BioNTech нь Хитадай [[Fosun Pharma]] хампаанитай хамтаран хүгжөөлгэ, соносхол, эльгээхэ эрхын шэглэлээр ажалладаг ба вакциные '''Fosun–BioNTech COVID‑19 вакцина''' гэжэ хара хэлэндэ нэрлэһэн.<ref name="Fosun PR 20201216">{{cite press release|title=BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine|url=https://www.fosunpharma.com/en/news/news-details-3820.html|date=16 December 2020|access-date=2021-04-18|publisher=Fosun Pharma|archive-date=18 April 2021|archive-url=https://web.archive.org/web/20210418144020/https://www.fosunpharma.com/en/news/news-details-3820.html|url-status=live}}</ref><ref>{{cite news|title=BioNTech in China alliance with Fosun over potential coronavirus vaccine|date=16 March 2020|url=https://www.reuters.com/article/us-biontech-fosunpharma-vaccine-collabor-idUKKBN2130O5|access-date=19 March 2021|work=Reuters|quote=BioNTech struck a collaboration deal with Shanghai Fosun Pharmaceutical over the German biotech firm's rights in China to an experimental coronavirus vaccine, the latest gambit in a global race to halt the pandemic.|vauthors=Burger L|archive-date=14 April 2021|archive-url=https://web.archive.org/web/20210414205227/https://www.reuters.com/article/us-biontech-fosunpharma-vaccine-collabor-idUKKBN2130O5|url-status=live}}</ref><ref>{{cite news|title=BioNTech, Fosun start Phase II trial of COVID-19 vaccine in China|date=25 November 2020|url=https://www.reuters.com/article/us-health-coronavirus-biontech-fosunphar-idUSKBN2850ZZ|access-date=20 March 2021|work=Reuters|quote=BioNTech and Shanghai Fosun Pharmaceutical said on Wednesday they would launch a Phase{{nbs}}II clinical trial of BioNTech's experimental COVID-19 vaccine in China.|archive-date=14 April 2021|archive-url=https://web.archive.org/web/20210414205231/https://www.reuters.com/article/us-health-coronavirus-biontech-fosunphar-idUSKBN2850ZZ|url-status=live}}</ref><ref name="Fosun PR 20210227">{{cite press release|title=BioNTech and Fosun Pharma Jointly Announce the Arrival of the First Batch of COVID-19 mRNA Vaccine in Hong Kong and Macau|publisher=[[Fosun Pharma]]|date=27 February 2021|url=https://www.fosunpharma.com/en/news/news-details-3829.html|access-date=15 April 2021|archive-date=15 April 2021|archive-url=https://web.archive.org/web/20210415191727/https://www.fosunpharma.com/en/news/news-details-3829.html|url-status=live}}</ref><ref>{{cite news|title=BioNTech and China partner, not Pfizer, to produce HK shots|url=https://www.thestandard.com.hk/section-news/section/11/225661/BioNTech-and-China-partner,-not-Pfizer,-to-produce-HK-shots|website=[[The Standard (Hong Kong)|The Standard]]|date=14 December 2020|access-date=18 April 2021|archive-date=18 April 2021|archive-url=https://web.archive.org/web/20210418142309/https://www.thestandard.com.hk/section-news/section/11/225661/BioNTech-and-China-partner,-not-Pfizer,-to-produce-HK-shots|url-status=live}}</ref> Вакциные балсанда тариха замаар хэдэг.

== Эмнэлгын хэрэглэлгэ ==
Pfizer–BioNTech COVID-19 вакциные COVID-19-һээ уридшалан һэргылхэ, [[SARS-CoV-2]] вирусай халдабариһаа хамгаалха зорилгоор ашагладаг. Вакциные "сагаанһаа шара-сагаан үнгэтэй, арюун, консервантгүй, балсан тарихада хүлдөөhэн" хэлбэреэр олон тунгаар хэһэн флакондо ниилүлэгдэдэг. Вакциные хэрэглэхһээ үмэнэ таhалгын температуралуу гэсгээжэ, [[Дабһанай уусамал|дабһанай уусамалда]] шэнгэрүүлхэ хэрэгтэй.

Эхинэй курсинь хоёр дозоһоо бүридэхэ ба гурбадахи нэмэлтэ дозо зайлашагүй гэһэн баталалга байхагүй юм. [[Дэлхэйн элүүр мэндын байгуулга|Дэлхэйн Элүүр Мэндын Байгуулга]] (ДЭМБ) дозын хоорондо 3-4 долоон хоногой зайтай байхые зүблэжэ байна. Хоёрдохи дозые 12 долоон хоног хүрэтэр хойшолуулхань наhатай хүнүүдтэ иммунитет тогтохо шадабариие ехэдхэдэг ба [[SARS-CoV-2-ай Альфа хубилбари|Альфа хубилбариин]] эсэргүү нэгэдэхи дозын үрэ дүн 10 долоон хоног үргэлжэлдэг болохые харуулжа байна. Тиимэһээ хангамжа хизаарлагданги байгаа тохёолдолдо наһа баралтаһаа зайлахын тулада ДЭМБ-һаа нэн приоритетэй бүлэгүүдэдэ нэгэдэхи дозые үндэр олгохын тулада хоёрдохи дозые тариха хугасааг 12 долоон хоног хүрэтэр хойшолуулхые зүблэжэ байна.<ref name="who-guidance">{{cite techreport|type=Guidance|title=Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing|id=WHO/2019-nCoV/vaccines/SAGE_recommendation//BNT162b2/2021.2|institution=World Health Organization|date=15 June 2021|url=https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1}}</ref>

=== Үрэ дүн ===
{| class="wikitable sortable"
|+Үбшэнэй хүндын зэрэгээр үрэ дүнтэй байдал
! rowspan="2" |[[SARS-CoV-2-ай хубилбаригууд|Хубилбари]]
! colspan="3" |Хоёр дозо
! colspan="3" |Нэгэ дозо
|-
!Шэнж тэмдэггүй
!Шэнж тэмдэгтэй
!Госпитализаци
!Шэнж тэмдэггүй
!Шэнж тэмдэгтэй
!Госпитализаци
|-
|Бусад эрьежэ байһан
|{{good|{{Estimate|92|88|95|unit=%|mini=auto}}<ref>{{cite journal |vauthors=Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B, Balicer RD |display-authors=6 |date=April 2021 |title=BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting |journal=New England Journal of Medicine |volume=384 |issue=15 |at=Table 2 |doi=10.1056/NEJMoa2101765 |pmc=7944975 |pmid=33626250}}</ref>|align=left}}
|{{good|{{Estimate|94|87|98|unit=%|mini=auto}}|align=left}}
|{{good|{{Estimate|87|55|100|unit=%|mini=auto}}|align=left}}
|{{good|{{Estimate|60|53|66|unit=%|mini=auto}}|align=left}}
|{{good|{{Estimate|66|57|73|unit=%|mini=auto}}|align=left}}
|{{good|{{Estimate|78|61|91|unit=%|mini=auto}}|align=left}}
|-
|[[SARS-CoV-2-ай Альфа хубилбари|Альфа]]
|{{good|{{Estimate|90|86|92|unit=%|mini=auto}}<ref name=":2">{{cite journal |vauthors=Abu-Raddad LJ, Chemaitelly H, Butt AA |title=Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants |at=Table 1 |journal=New England Journal of Medicine |date=5 May 2021 |pmid=33951357 |pmc=8117967 |doi=10.1056/NEJMc2104974 |doi-access=free |url=https://www.nejm.org/doi/full/10.1056/NEJMc2104974 }}</ref>|align=left}}
|{{good|{{Estimate|93|90|96|unit=%|mini=yes}}<ref>{{cite journal |vauthors=Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G, Myers R |display-authors=6 |date=2021-05-24 |title=Effectiveness of COVID-19 vaccines against the B.1.617.2 variant |at=Table 2 |url=https://www.medrxiv.org/content/10.1101/2021.05.22.21257658v1 |via=[[medRxiv]] |type=[[Preprint]] |doi=10.1101/2021.05.22.21257658}}</ref><ref name="briefing17">{{cite techreport |type=Briefing |title=SARS-CoV-2 variants of concern and variants under investigation in England, technical briefing 17 |id=GOV-8576 |institution=Public Health England |date=2021-06-25 |url=https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/996740/Variants_of_Concern_VOC_Technical_Briefing_17.pdf |format=PDF |access-date=2021-06-26}}</ref>|align=left}}
|{{good|{{Estimate|95|78|99|unit=%|mini=auto}}|align=left}}
|{{Estimate|30|23|36|unit=%|mini=auto}}
|{{Estimate|49|43|55|unit=%|mini=auto}}
|{{good|{{Estimate|83|62|93|unit=%|mini=auto}}|align=left}}
|-
|[[SARS-CoV-2-ай Бета хубилбари|Бета]]
|{{good|{{Estimate|75|71|79|unit=%|mini=auto}}<ref name=":2" />|align=left}}
|{{n/a|Not reported}}
|{{good|{{Estimate|100|74|100|unit=%|mini=auto}}<ref name=":2"/>|align=left}}
|{{Estimate|17|10|23|unit=%|mini=auto}}
|{{n/a|Not reported}}
|{{Estimate|0|0|19|unit=%|mini=auto}}
|-
|[[SARS-CoV-2-ай Гамма хубилбари|Гамма]]
|{{n/a|Not reported}}
|{{n/a|Not reported}}
|{{n/a|Not reported}}
|{{n/a|Not reported}}
|{{n/a|Not reported}}
|{{n/a|Not reported}}
|-
|[[SARS-CoV-2-ай Дельта хубилбари|Дельта]]
|{{good|{{Estimate|79|75|82|unit=%|mini=auto}}<ref name="effectiveness-scotland">{{cite journal |vauthors=Sheikh A, McMenamin J, Taylor B, Robertson C |date=2021-06-14 |title=SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness |at=Table S4 |url=https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01358-1/abstract |journal=The Lancet |doi=10.1016/S0140-6736(21)01358-1 |issn=0140-6736 |pmid=34139198|pmc=8201647 }}</ref>|align=left}}
|{{good|{{Estimate|88|78|93|unit=%|mini=auto}}|align=left}}
|{{good|{{Estimate|96|86|99|unit=%|mini=auto}}<ref>{{cite techreport |type=[[Preprint]] |via=Knowledge Hub |vauthors=Stowe J, Andrews N, Gower C, Gallagher E, Utsi L, Simmons R, Thelwall S, Tessier E, Groves N, Dabrera G, Myers R, Campbell C, Amirthalingam G, Edmunds M, Zambon M, Brown K, Hopkins S, Chand M, Ramsay M, Bernal JL |display-authors=6 |title=Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant |at=Table 1 |institution=Public Health England |date=2021-06-14 |url=https://khub.net/documents/135939561/479607266/Effectiveness+of+COVID-19+vaccines+against+hospital+admission+with+the+Delta+%28B.1.617.2%29+variant.pdf/1c213463-3997-ed16-2a6f-14e5deb0b997?t=1623689315431}}</ref><ref name="briefing17"/>|align=left}}
|{{Estimate|30|17|41|unit=%|mini=auto}}
|{{Estimate|33|8|51|unit=%|mini=auto}}
|{{good|{{Estimate|94|46|99|unit=%|mini=auto}}|align=left}}
|}

== Түүхэ ==

=== Зүбшөөрэл ===
{{#section:COVID-19-дэ эсэргүй вакцинай зүбшөөрэлэй жагсаалта|pfizerauthmap}}
{{See also|COVID-19-дэ эсэргүй вакцинай зүбшөөрэлэй жагсаалта#Pfizer–BioNTech}}

== Зүүлтэ ==
<references />

== Холбоо ==

[[Категори:ATC код олгогүй эм]]
[[Категори:BioNTech]]
[[Категори:Клиникын туршалга]]
[[Категори:COVID-19-дэ эсэргүү вакцина]]
[[Категори:COVID-19-эй халдабарита үбшэнэй медицинскэ харюу]]
[[Категори:Pfizer]]
[[Категори:2020 ондо нэбтэрүүлэгдэһэн бүтээгдэхүүн]]
[[Категори:РНХ-вакцина]]
